Biotech News
Related news
OCSOculis2026-05-29 19:06 EST
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
OCSOculis2026-05-11 20:07 EST
Oculis Reports Q1 2026 Financial Results and Provides Company Update
TARSTarsus Pharmaceuticals2026-09-29 12:30 EST
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
PRQRProQR Therapeutics2026-09-23 12:00 EST
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
SGHTSight Sciences2026-10-01 11:05 EST
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
RHHBYRoche Holdings AG2026-09-23 05:00 EST
Change in Roche’s Board of Directors
OTLKOutlook2026-08-06 12:45 EST
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
PRQRProQR Therapeutics2026-05-11 12:00 EST
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-10-01 06:00 EST
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
OCSOculis2026-09-30 21:32 EST
Oculis Announces Resignation of Lionel Carnot from Board of Directors
OCSOculis2026-09-17 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-08-24 08:00 EST
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
OCSOculis2026-08-14 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Stock data
- Close
- 8.73 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States